Abbott, Others Marketed Stents Off-Label: Suit

By Ryan Davis

Law360, New York (January 15, 2010, 4:30 PM ET) -- Boston Scientific Corp., Abbott Laboratories and Cordis Corp. engaged in an off-label marketing scheme to promote digestive tract stents for unapproved use in other parts of the body, according to a recently unsealed whistleblower suit by a former medical device executive.

Kevin Colquitt, a former regional sales director for Guidant, which is now part of Boston Scientific, filed the False Claims Act suit in September 2006 in the U.S. District Court for the Northern District of Texas. Judge Barbara Lynn ordered the 100-page complaint unsealed on...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles